The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer
Open accessAbstract
SN-38 is the active metabolite of irinotecan and it is metabolised through conjugation by uridine diphosphate glucuronosyl transferase (UGT1A1). The major toxicity of irinotecan therapy is diarrhoea, which has been related to the enzymatic activity of UGT1A1. We examined the influence of the UGT1A1 gene promoter polymorphism in the toxicity profile, in the response rate and in the overall survival (OS) in 95 patients with metastatic colorectal cancer treated with an irinotecan-containing chemotherapy. Genotypes were determined by analysing the sequence of TATA box of UGT1A1 of genomic DNA from the patients. Clinical parameters and genotypes were compared by univariate and multivariate statistical methods. The more frequent adverse effects were asthenia (34 patients), diarrhoea (29 patients) and neutropenia (20 patients). Severe diarrhoea was observed in 7/10 homozygous (70%) and 15/45 heterozygous (33%) in comparison to 7/40 (17%) wild-type patients (P=0.005). These results maintained the statistical significance in logistic regression analysis (P=0.01) after adjustment for other clinical relevant variables. The presence of severe haematological toxicity increased from wild-type patients to UGT1A1(*)28 homozygotes, but without achieving statistical significance. No relationship was found between the UGT1A1(*)28 genotypes and infection, nausea or mucositis. In univariate studies, patients with the UGT1A1(*)28 polymorphism showed a trend to a poorer OS (P=0.09). In the multivariate analysis, the genotype was not related to clinical response or to OS. The role of the UGT1A1 genotype as a predictor of toxicity in cancer patients receiving irinotecan demands the performance of a randomized trial to ascertain whether genotype-adjusted dosages of the drug can help to establish safe and effective doses not only for patients with the UGT1A1(*)28 homozygous genotype but also for those with the most common UGT1A1 6/6 or 6/7 genotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A simple salting out procedure for extracting DNA from human nucleated cells
Miller, S. A., Dykes, D. D., & Polesky, H. F. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.3.1215 · Cited by 20,330
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Rougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03085-2 · Cited by 992
Ando, Y., Saka, H., Ando, M., Sawa, T., Muro, K., Ueoka, H., Yokoyama, A., Saitoh, S., Shimokata, K., & Hasegawa, Y. (2000) · PubMed · Cited by 783
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · PubMed · Cited by 740
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
Iyer, L., Das, S., Janisch, L., Wen, M., Ramírez, J., Karrison, T., Fleming, G. F., Vokes, E. E., Schilsky, R. L., & Ratain, M. J. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500072 · Cited by 720
Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K., Tephly, T. R., Coffman, B. L., & Ratain, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci915 · Cited by 686
Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome
Monaghan, G., Ryan, M., Hume, R., Burchell, B., & Seddon, R. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91273-8 · Cited by 585
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., & Ratain, M. J. (1994) · PubMed · Cited by 501
Ritter, J. K., Chen, F., Sheen, Y. Y., Tran, H. M., Kimura, S., Yeatman, M. T., & Owens, I. S. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50724-4 · Cited by 473
Jaxel, C., Kohn, K. W., Wani, M. C., Wall, M. E., & Pommier, Y. G. (1989) · PubMed · Cited by 449
Kadakol, A., Ghosh, S. S., Sappal, B. S., Sharma, G., Chowdhury, J. R., & Chowdhury, N. R. (2000) · Human Mutation · doi:10.1002/1098-1004(200010)16:4<297::aid-humu2>3.0.co;2-z · Cited by 387
IYER, L., HALL, D., DAS, S., MORTELL, M., RAMIREZ, J., KIM, S., DIRIENZO, A., & RATAIN, M. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70078-0 · Cited by 356
Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview
Vanhoefer, U., Harstrick, A., Achterrath, W., Cao, S., Seeber, S., & Rustum, Y. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1501 · Cited by 326
Irinotecan pathway genotype analysis to predict pharmacokinetics.
Mathijssen, R. H. J., Marsh, S., Karlsson, M. O., Xie, R., Baker, S. D., Verweij, J., Sparreboom, A., & McLeod, H. L. (2003) · PubMed · Cited by 258
Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports
Wasserman, E., Myara, A., Lokiec, F., Goldwasser, F., Trivin, F., Mahjoubi, M., Misset, J. L., & Cvitkovic, E. (1997) · Annals of Oncology · doi:10.1023/a:1008261821434 · Cited by 213
UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan
Ando, Y., Saka, H., Asai, G., Sugiura, S., Shimokata, K., & Kamataki, T. (1998) · Annals of Oncology · doi:10.1023/a:1008438109725 · Cited by 207
Haaz, M., Rivory, L. P., Riché, C., Vernillet, L., & Robert, J. (1998) · PubMed · Cited by 172
Slatter, J. G., Su, P., Sams, J. P., Schaaf, L. J., & Wienkers, L. C. (1997) · PubMed · Cited by 152
Impact of Body-Size Measures on Irinotecan Clearance: Alternative Dosing Recommendations
Mathijssen, R. H. J., Verweij, J., de Jonge, M. J. A., Nooter, K., Stoter, G., & Sparreboom, A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.81 · Cited by 113
Owens, I. S., & Ritter, J. K. (1995) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(08)60882-x · Cited by 76
Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
Zamboni, W. C., Stewart, C. F., Cheshire, P. J., Richmond, L. B., Hanna, S. K., Luo, X., Poquette, C. A., McGovren, J. P., Houghton, J. A., & Houghton, P. J. (1998) · PubMed · Cited by 46
Cited by
Pharmacologic resistance in colorectal cancer: a review
Hammond, W. A., Swaika, A., & Mody, K. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015614530 · Cited by 519
UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters
Hoskins, J. M., Goldberg, R. M., Qu, P., Ibrahim, J. G., & McLeod, H. L. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm115 · Cited by 469
Toffoli, G., Cecchin, E., Corona, G., Russo, A., Buonadonna, A., D'Andrea, M., Pasetto, L. M., Pessa, S., Errante, D., De Pangher, V., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.5400 · Cited by 338
Minami, H., Sai, K., Saeki, M., Saito, Y., Ozawa, S., Suzuki, K., Kaniwa, N., Sawada, J.-I., Hamaguchi, T., Yamamoto, N., et al. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328014341f · Cited by 289
Ruzzo, A., Graziano, F., Loupakis, F., Rulli, E., Canestrari, E., Santini, D., Catalano, V., Ficarelli, R., Maltese, P., Bisonni, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1844 · Cited by 266
Metadata
- Authors
- Marcuello, E., Altés, A., Menoyo, A., del Rio, E., Gómez-Pardo, M., & Baiget, M.
- Venue
- British Journal of Cancer
- Published
- 2004-07-27
- Volume
- 91
- Issue
- 4
- Pages
- 678-682
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2038750466
- Cited by
- 315
- References
- 24
- FWCI
- 18.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.